Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $5.80

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $5.17.

A number of analysts recently weighed in on SGMO shares. Wells Fargo & Company reduced their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating for the company in a report on Tuesday, December 31st. StockNews.com lowered Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. Truist Financial cut their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday.

Remove Ads

Sangamo Therapeutics Stock Up 2.6 %

Sangamo Therapeutics stock traded up $0.02 during trading hours on Friday, hitting $0.87. 5,909,687 shares of the company traded hands, compared to its average volume of 7,653,708. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The firm has a market cap of $181.11 million, a P/E ratio of -1.16 and a beta of 1.49. The firm's 50-day simple moving average is $1.09 and its two-hundred day simple moving average is $1.41.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.70 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, equities research analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. E Fund Management Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter worth $25,000. JPMorgan Chase & Co. increased its stake in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 21,793 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in Sangamo Therapeutics during the 4th quarter valued at approximately $28,000. Finally, Shelton Wealth Management LLC acquired a new stake in Sangamo Therapeutics in the 4th quarter valued at approximately $29,000. Institutional investors own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.